← Back to Search

Remote Assessment Technology for Multiple Sclerosis

Phase 2
Waitlist Available
Research Sponsored by Transparency Life Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males and females between the ages of 18 and 64
Baseline score of 0-5.5 on Kurtzke's Expanded Disability Status Scale (EDSS)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 6
Awards & highlights

Study Summary

This trial is testing whether the MSFC can be done at home using video conferencing technology.

Who is the study for?
Adults aged 18-64 with a documented diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) and an EDSS score between 0-5.5 can join this trial. They must have normal blood pressure, not be too low or high, and someone at home to help during tests. People with very low/high blood pressure or slow heart rate (<50 bpm) cannot participate.Check my eligibility
What is being tested?
The study is testing the use of the Multiple Sclerosis Functional Composite (MSFC), both at a study site and remotely from home using technology like video calls. This is to prepare for a future phase 2 trial evaluating lisinopril in treating multiple sclerosis.See study design
What are the potential side effects?
Since this stage of the trial focuses on calibrating assessment tools rather than medication effects, specific side effects are not detailed here.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 64 years old.
Select...
My disability level is moderate, as measured by a specific scale.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
MSFC Score Comparison
Mobile 9-hole Peg Test Time Comparison
Mobile Paced Auditory Serial Addition Test Score Comparison
+2 more

Trial Design

2Treatment groups
Active Control
Group I: Group 2Active Control2 Interventions
Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 1.
Group II: Group 1Active Control2 Interventions
Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 2.

Find a Location

Who is running the clinical trial?

Transparency Life SciencesLead Sponsor
1 Previous Clinical Trials
51 Total Patients Enrolled
Tomasz Sablinski, MD, PhDStudy DirectorTransparency Life Sciences
2 Previous Clinical Trials
312 Total Patients Enrolled

Media Library

Multiple Sclerosis Functional Composite Clinical Trial Eligibility Overview. Trial Name: NCT02369926 — Phase 2
Multiple Sclerosis Research Study Groups: Group 2, Group 1
Multiple Sclerosis Clinical Trial 2023: Multiple Sclerosis Functional Composite Highlights & Side Effects. Trial Name: NCT02369926 — Phase 2
Multiple Sclerosis Functional Composite 2023 Treatment Timeline for Medical Study. Trial Name: NCT02369926 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age range of participants in this clinical trial limited to individuals 30 years or younger?

"The age range of participants in this trial is delineated to be between 18 and 64. For those under the legal age of consent, there are 43 trials available while 391 clinical studies are open for enrolment by individuals older than 65 years old."

Answered by AI

Is enrollment currently open for this experimental trial?

"As outlined on clinicaltrials.gov, this specific research study is not presently looking to recruit any participants. It was initially posted in November 2014 and last updated October 2017; yet there are still 549 other medical trials currently admitting patients."

Answered by AI

What risks would individuals incur by exposure to Group 1?

"Due to the lack of evidence supporting efficacy, Group 1 received a rating of 2 on our safety scale. This is because it's only in Phase 2 and there has been some data collected regarding its safety but not its efficacy."

Answered by AI

What criteria must a person meet to be eligible for the study?

"This medical research is looking for 20 adults (18-64 years old) with multiple sclerosis, who are in an acute relapsing phase. To be eligible, candidates must have Kurtzke's Expanded Disability Status Scale scores ranging from 0 to 5.5 and a person available at home that can physically support them if needed during the walk test."

Answered by AI

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What site did they apply to?
Icahn School of Medicine at Mount Sinai
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis
2014. "Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02369926.
All > Primary Progressive Multiple Sclerosis
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top